Cantor initiated Amgen (NASDAQ:AMGN) coverage with an overweight rating, asserting it was a “big believer” in the biotech ...

The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Federman & Sherwood investigates Amgen, Inc. for data breach. Amgen became aware of a cybersecurity incident that involved one of their service providers, Sirva Relocation, LLC and its parent company ...

On 4, 2024, Amgen, Inc. filed a notice of data breach with the Attorney General of Massachusetts after discovering that ...

Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded ...

As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...

Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...

Beyond MariTide, Amgen has a rich pipeline with more than 30 phase 3 programs. Some are for existing medicines seeking label ...

Amgen said on Tuesday its experimental drug, rocatinlimab, met the main goals in a late stage study testing it as a treatment ...

Amgen shares fell 4.5% after the biotech revealed disappointing study results for two closely watched drug candidates. The company, in a call with analysts and investors, reported positiv ...

Amgen (AMGN) shares were down 5% Wednesday, the day after the company reported Phase 3 results for its drugs rocatinlimab and ...